HCPCS J9039: Blinatumomab Injection, 1 Microgram - OpenPayer

Summary & Overview

HCPCS J9039: Blinatumomab Injection, 1 Microgram

HCPCS Level II code J9039 denotes the billed unit for blinatumomab at 1 microgram and is used when reporting supply of this oncology biologic. Blinatumomab is a targeted immunotherapy with administration typically occurring in infusion-capable settings such as hospital outpatient departments or oncology clinics. Use of this code matters nationally because it supports accurate drug utilization tracking, reimbursement for high-cost oncology agents, and claims clarity for both commercial and public payers.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of how J9039 is applied on claims, common billing practices for unit-based oncology drug codes, and the clinical context for blinatumomab administration. The publication also summarizes available benchmarks and policy considerations relevant to drug coding, billing unitization, and site-of-service implications. Data not available in the input are noted where applicable; the content focuses on the code definition, typical service settings, and the landscape of payers likely to process J9039 claims.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ9039HCPCS Level IIblinatumomaboncology druginfusiondrug administrationunit-based codingbilling policyoutpatient infusion

Billing Code Overview

HCPCS Level II code J9039 describes injection, blinatumomab, 1 microgram. This code represents administration of the bispecific T-cell engager agent blinatumomab, measured per microgram of medication supplied.

Service type: Drug administration for an infused or injected oncology biologic
Typical site of service: Hospital outpatient infusion center, physician office infusion suite, or specialized oncology clinic

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult or pediatric individual with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) being treated with blinatumomab. The therapy is administered as an intravenous infusion requiring careful inpatient or outpatient oncology infusion center monitoring due to risks of cytokine release syndrome and neurotoxicity. Prior to initiation, the patient undergoes baseline laboratory testing (CBC, CMP), infectious disease screening, and neurologic assessment. The first dose is often started in a higher-acuity setting (hospital or infusion center with escalation ability) for close observation for the initial 24–48 hours; subsequent doses may be delivered in an outpatient infusion center with frequent follow-up visits and periodic labs. Documentation includes diagnosis, dose in micrograms or total milligrams, infusion start/stop times, premedications, adverse reactions, and any treatment interruptions or dose modifications. Billing uses the HCPCS Level II code J9039 reported per microgram of blinatumomab; medication wastage, drug preparation, and separate supportive services are documented per payer rules.

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug discarded/unused	Append when a portion of blinatumomab is discarded and payer requires reporting of wasted drug units.

HCPCS J9229: Inotuzumab Ozogamicin Injection, 0.1 mg

HCPCS-J9220-INDIGOTINDISULFONATE-INJECTION-1MG

HCPCS J9220: Injection of Indigotindisulfonate Sodium, 1 mg

HCPCS-J9198-GEMCITABINE-100MG-INFUSION

HCPCS J9198: Gemcitabine Hydrochloride Injection, 100 mg

HCPCS-J9098-CYTARABINE-LIPOSOME-INJECTION-10MG

HCPCS Level II J9098: Injection, cytarabine liposome, 10 mg

HCPCS-J9308-RAMUCIRUMAB-INJECTION-5MG

HCPCS Level II J9308: Injection of Ramucirumab, 5 mg

HCPCS-J9320-INJECTION-STREPTOZOCIN-1G

HCPCS Level II J9320: Injection, streptozocin, 1 gram

HCPCS-J9184-GEMCITABINE-200MG-INJECTION

HCPCS J9184: Gemcitabine Hydrochloride (avyxa), 200 mg Injection

HCPCS-J9312-RITUXIMAB-INJECTION-10MG

HCPCS J9312: Rituximab Injection, 10 mg

HCPCS-J9153-LIPOSOMAL-DAUNORUBICIN-CYTARABINE-INJECTION

HCPCS J9153: Liposomal Daunorubicin and Cytarabine Injection

HCPCS-J9247-MELPHALAN-FLUFENAMIDE-INJECTION-1MG

HCPCS Level II J9247: Injection, melphalan flufenamide, 1mg

Showing 1–10 of 227

Taxonomy Code	Specialty	Notes
`207RG0100X`	Hematology & Oncology	Medical oncologists and hematologist-oncologists who prescribe and oversee blinatumomab therapy.
`364S00000X`	Infusion Therapy	Infusion nurses and infusion centers providing medication administration and monitoring.
`3336P0800X`	Pediatric Hematology-Oncology	Specialists managing pediatric ALL patients receiving blinatumomab.
`208000000X`	Internal Medicine	Hospitalists or internists involved in inpatient initiation or management of complications.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C91.10`	Acute lymphoblastic leukemia, B-cell, not having achieved remission	Primary indication for blinatumomab in relapsed or refractory B-cell precursor ALL.
`C91.11`	Acute lymphoblastic leukemia, B-cell, in remission	May be used to document maintenance or consolidation treatment context when assessing residual disease.
`C91.12`	Acute lymphoblastic leukemia, B-cell, in relapse	Common scenario prompting use of blinatumomab for relapsed disease.
`D61.819`	Other drug-induced aplastic anemia	Relevant as a potential complication or part of differential when cytopenias occur during therapy.
`R41.840`	Attention and concentration deficit	Relevant for documenting neurologic adverse events or monitoring for neurotoxicity related to blinatumomab.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Used for billing initial continuous infusion administration time segments when applicable for short infusions or loading periods.
`96366`	Intravenous infusion, each additional hour (List separately in addition to code for primary infusion)	Used to report each additional hour of continuous infusion time beyond the first hour when payer allows time-based infusion reporting alongside medication J-code billing.
`36415`	Collection of venous blood by venipuncture	Performed for required baseline and monitoring laboratory testing before and during therapy.
`36556`	Insertion of tunneled centrally inserted central venous catheter, age 5 years or older	Performed when long-term central venous access is placed to administer continuous infusion of blinatumomab.
`99214`	Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	Used for outpatient oncology follow-up visits evaluating response, toxicity, and ongoing management during infusion cycles.

OpenPayer